Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174343
Status:
COMPLETED
Last Update Posted:
2011-04-22
First Post:
2005-09-09
Brief Title:
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane Aromasin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None